{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:31:34Z","timestamp":1760549494013},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T00:00:00Z","timestamp":1394841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cyclosporin is used for moderate to severe psoriasis and improves not only the skin lesions but also quality of life of the patients. To improve its safe use, we evaluated a low\u2010dose, intermittent regimen of cyclosporin in the treatment of psoriasis vulgaris. Seventy\u2010three patients received approximately 2.5\u00a0mg\/kg per day of cyclosporin microemulsion twice daily before breakfast and dinner for 2\u201312\u00a0weeks until 75% reduction was achieved in <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>soriasis <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>rea and <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>everity <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>ndex (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) score. When the skin lesions relapsed after cessation of cyclosporin and showed less than 50% reduction from baseline in <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> score, cyclosporin was restarted. This cessation and restart cycle was repeated if necessary. Treatment outcomes were assessed at 12, 48 and 96\u00a0weeks after initiation of the therapy. The initial dose of cyclosporin was 2.32\u00a0\u00b1\u00a00.27 (standard deviation [<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>]) mg\/kg per day. At baseline, the mean <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> score was 11.3\u00a0\u00b1\u00a05.3 (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>). An average of 49.8\u00a0\u00b1\u00a023.8 (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>) days of the therapy achieved <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75% reduction. In 20 of 73 patients, the second course of cyclosporin was required. The mean interval between the first and second course was 94\u00a0days. An average of 60.8\u00a0\u00b1\u00a026.9\u00a0days was required to achieve <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75% reduction in the second course, which was not significantly longer than that in the first course. Only six patients required cyclosporin for 96\u00a0weeks. The adverse effects included one case of hypertension. Our study suggests that low\u2010dose, intermittent cyclosporin microemulsion is efficacious for the treatment of moderate to severe psoriasis.<\/jats:p>","DOI":"10.1111\/1346-8138.12455","type":"journal-article","created":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T06:46:47Z","timestamp":1394866007000},"page":"377-381","source":"Crossref","is-referenced-by-count":10,"title":["Efficacious treatment of psoriasis with low\u2010dose and intermittent cyclosporin microemulsion therapy"],"prefix":"10.1111","volume":"41","author":[{"given":"Taisuke","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Dermatology Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukumi","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wakayama Medical University Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Iwatsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Matsue","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chiba University Graduate School of Medicine Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine University of Yamanashi Chuo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takigawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Tokura","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hamamatsu University School of Medicine Hamamatsu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2012.04337.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2012.07919.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00390.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2006.00022.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00275.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00305.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01228.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2011.565017"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.11.006"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.12455","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.12455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:06:15Z","timestamp":1695549975000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.12455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,15]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/1346-8138.12455"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.12455","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,15]]}}}